Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.
President Trump has threatened to impose escalating tariffs on a wide range of industries, including automobiles, pharmaceuticals, lumber, semiconductors, and oil and gas imports from countries dealing with Venezuela, signaling plans for more sweeping trade duties.
A groundbreaking mRNA vaccine demonstrated remarkable potential in preventing pancreatic cancer recurrence, with some patients remaining cancer-free for over 3 years in a small clinical trial, offering new hope by training the immune system to recognize and attack cancer cells.
TxAgent, an AI agent leveraging multi-step reasoning and real-time biomedical knowledge retrieval, revolutionizes personalized drug treatment with 92.1% accuracy, outperforming leading models and ensuring treatment recommendations align with clinical guidelines to reduce adverse events.
Insilico Medicine, an AI-driven drug discovery company, raised $110 million in Series E funding to propel its AI platform Pharma.AI, advance its drug pipeline, and bolster biopharmaceutical R&D, harnessing biology, clinical data, and generative chemistry for innovative drug development.
Rare diseases affect millions but face an uphill battle for diagnosis, treatment, and research due to their rarity, despite efforts like federal incentives and patient advocacy, underscoring the need for increased focus to unlock medical insights and cures.
ReviveMed unveiled an AI-powered metabolomics platform with mzLearn algorithm for automated metabolite detection, enabling pre-trained generative AI models that outperformed clinical risk scores in predicting renal cell carcinoma outcomes, paving the way for precision medicine breakthroughs.
In a groundbreaking AI breakthrough, FragFold, an innovative system leveraging AlphaFold's machine learning capabilities, accurately predicts protein fragments that can inhibit target proteins, experimentally confirming over 50% of its predictions and unlocking new frontiers in drug discovery by enabling deeper insights into protein interactions.
Evo 2, a groundbreaking AI tool, unlocks the secrets of nature's genetic code, enabling rapid protein discovery by virtually predicting the form and function of proteins encoded in the DNA of all living and extinct species, potentially revolutionizing biological research and accelerating scientific breakthroughs.